Cerebrospinal Fluid Tau and Amyloid β Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients

Spies, Petra E.; Claassen, J.A.H.R.; Slats, Diane; Rikkert, Marcel G M Olde; Verbeek, Marcel M.; Kessels, Roy P. C.

doi:10.1017/s1092852900000560

Cited by 5 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results stress the correct capacity in the subtest of orientation and abstract thought in the MCI group versus AD group, which shows deficits in these tests. Regarding the AD group, the mean total score obtained in the CAMCOG-R rated the cognitive impairment as mild/moderate, and is similar to those obtained by other researchers (Garre-Olmo, 2008; Heinik & Solomesch, 2007;Spies et al, 2010).…”

Section: Discussionsupporting

confidence: 87%

Attention and inhibition in Mild Cognitive Impairment and Alzheimer's Disease

Piquero¹,

Begega²,

Menéndez³

et al. 2013

Escritos Psicología

View full text Add to dashboard Cite

Mild cognitive impairment is understood as a cognitive deficit of insufficient severity to fulfil the criteria for Alzheimer’s disease. Many studies have attempted to identify which cognitive functions are most affected by this type of impairment and which is the most sensitive neuropsychological test for early detection. This study investigated sustained and selective attention, processing speed, and the inhibition process using a sample of people divided into three groups mild cognitive impairment, Alzheimer disease and cognitively healthy controls selected and grouped based on their scores in the Mini Mental State Examination and Cambridge Cognitive Examination-revised. Three tests from the Cambridge Neuropsychological Test Automated Battery (Motor Screening Task, Stop Signal Task and Reaction time) were used as well as the d2 attention test. The results show that that participants with mild cognitive impairment and Alzheimer disease showed lower levels of concentration compared with the cognitively healthy controls group in the d2 test and longer reaction times in the Cambridge Neuropsychological Test Automated Battery, although the differences were not marked in the latter test. The impairments in basic cognitive processes, such as reaction time and sustained attention, indicate the need to take these functions into account in the test protocols when discriminating between normal aging and early and preclinical dementia processes.

show abstract

Section: Discussionsupporting

confidence: 87%

Attention and inhibition in Mild Cognitive Impairment and Alzheimer's Disease

Piquero¹,

Begega²,

Menéndez³

et al. 2013

Escritos Psicología

View full text Add to dashboard Cite

show abstract

“…We did not find any significant correlations between CSF biomarkers levels and CAMCOG total scores when analyzed by diagnostic subgroup (controls, aMCI, naMCI, AD), which is in line with some previous reports, 12,45 but in disagreement a number of studies which reported associations between CSF biomarkers and cognitive measures in specific diagnostic groups. Focusing on each biomarker separately, we found some studies highlighting associations between CSF Ab 42 levels and cognition in cognitively normal elderly population, 46 in patients with subjective memory complaints, 22,47 and in patients with aMCI.…”

Section: Findings By Diagnostic Subgroupsupporting

confidence: 91%

AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State

Ibarra

Radanovic

Pais

et al. 2020

J Geriatr Psychiatry Neurol

View full text Add to dashboard Cite

Aim: Associations between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) with the severity of cognitive impairment are unclear. We examined the correlations between CSF biomarkers and cognitive performance in the AD continuum. Methods: We studied 143 elderly patients: cognitively unimpaired (n = 51), mild cognitive impairment (MCI) amnestic (n = 55) and nonamnestic (n = 20), and mild AD (n = 17) assessed with the Cambridge Cognitive Test (CAMCOG). We correlated total CAMCOG and its subdomains with CSF Aβ42, T-tau, p-tau levels, and Aβ42/p-tau. Results: In the total sample, T-tau and Aβ42/p-tau correlated with the total CAMCOG ( P < .01); all biomarkers correlated with memory ( P < .001); T-tau correlated with language ( P < .01). Conclusion: Memory and T-tau levels may be the most suitable parameters to reflect cognitive/CSF biomarker correlations. At present, such correlations are of little use in routine clinical practice.

show abstract

“…A more thorough analysis revealed that Aβ 1-42 levels were associated with cognitive performance in the MCI and OD groups. Several studies have established this association in MCI, although focusing on isolated cognitive domains 10,28,29. Tau levels correlated with cognitive performance in the control, MCI, and non-AD dementia groups.…”

Section: Discussionmentioning

confidence: 97%

“…Rami et al27 also found a correlation between memory performance and CSF Aβ 1-42 levels in AD. However, negative reports have also been published 11,29. More recently, Mandecka et al30 described an association between the severity of verbal memory impairment and the degree of CSF abnormalities in AD.…”

Section: Discussionmentioning

confidence: 99%

Correlation between CSF biomarkers of Alzheimer’s disease and global cognition in a psychogeriatric clinic cohort

Radanovic

Oshiro

Freitas

et al. 2019

Braz. J. Psychiatry

View full text Add to dashboard Cite

Objective:The relationship between biomarkers of amyloid-beta aggregation (Aβ1-42) and/or neurodegeneration (Tau protein) in cerebrospinal fluid (CSF) and cognitive decline is still unclear. We aimed to ascertain whether CSF biomarkers correlate with cognitive performance in healthy and cognitively impaired subjects, starting from clinical diagnoses.Methods:We tested for correlation between CSF biomarkers and Mini-Mental State Examination (MMSE) scores in 208 subjects: 54 healthy controls, 82 with mild cognitive impairment (MCI), 46 with Alzheimer’s disease (AD), and 26 with other dementias (OD).Results:MMSE correlated weakly with all CSF biomarkers in the overall sample (r = 0.242, p < 0.0006). Aβ1-42 and MMSE correlated weakly in MCI (r = 0.247, p = 0.030), and moderately in OD (r = 0.440, p = 0.027). t-Tau showed a weak inverse correlation with MMSE in controls (r = -0.284, p = 0.043) and MCI (r = -0.241, p = 0.036), and a moderate/strong correlation in OD (r = 0.665), p = 0.0003). p-Tau correlated weakly with MMSE in AD (r = -0.343, p = 0.026) and moderately in OD (r = -0.540, p = 0.0005). The Aβ1-42/p-Tau ratio had a moderate/strong correlation with MMSE in OD (r = 0.597, p = 0.001).Conclusion:CSF biomarkers correlated best with cognitive performance in OD. t-Tau correlated weakly with cognition in controls and patients with MCI. In AD, only p-Tau levels correlated with cognitive performance. This pattern, which has been reported previously, seems to indicate that CSF biomarkers might not be reliable as indicators of disease severity.

show abstract

Cerebrospinal Fluid Tau and Amyloid β Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients

Cited by 5 publications

References 26 publications

Attention and inhibition in Mild Cognitive Impairment and Alzheimer's Disease

Attention and inhibition in Mild Cognitive Impairment and Alzheimer's Disease

AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State

Correlation between CSF biomarkers of Alzheimer’s disease and global cognition in a psychogeriatric clinic cohort

Contact Info

Product

Resources

About